Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial

This open-label, randomised phase 2 trial (ALIENOR; n=60) found no clinical benefit from adding bevacizumab to weekly paclitaxel (estimated 6-month progression-free rate of 71% for paclitaxel alone and 72% for the combination).

Source:

JAMA Oncology